Cargando…

One‐year Follow‐up Results of the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry

BACKGROUND: The high prevalence of atrial fibrillation (AF) in the very elderly population (aged >80 years) might be underestimated. The elderly are at increased risk of both fatal stroke and bleeding. The Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF)...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yutao, Wang, Hao, Kotalczyk, Agnieszka, Wang, Yutang, Lip, Gregory Y.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485828/
https://www.ncbi.nlm.nih.gov/pubmed/34621421
http://dx.doi.org/10.1002/joa3.12608
_version_ 1784577612508561408
author Guo, Yutao
Wang, Hao
Kotalczyk, Agnieszka
Wang, Yutang
Lip, Gregory Y.H.
author_facet Guo, Yutao
Wang, Hao
Kotalczyk, Agnieszka
Wang, Yutang
Lip, Gregory Y.H.
author_sort Guo, Yutao
collection PubMed
description BACKGROUND: The high prevalence of atrial fibrillation (AF) in the very elderly population (aged >80 years) might be underestimated. The elderly are at increased risk of both fatal stroke and bleeding. The Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry provides contemporary management strategies among the elderly Chinese patients in the new era of non‐vitamin K antagonists. OBJECTIVE: To present the 1‐year follow‐up data from the ChiOTEAF registry, focusing on the use of antithrombotic therapy, rate vs. rhythm control strategies, and determinants of mortality and stroke. METHODS: The ChiOTEAF registry analyzed consecutive AF patients presenting in 44 centers from 20 Chinese provinces from October 2014 to December 2018. Endpoints of interest were mortality, thromboembolism, major bleedings, cardiovascular comorbidities, and hospital re‐admissions. RESULTS: Of the 7077 patients enrolled at baseline, 657 patients (9.3%) were lost to the follow‐up and 435 deaths (6.8%) occurred. The overall use of anticoagulants remains low, approximately 38% of the entire cohort at follow‐up, with similar proportions of vitamin K antagonists (VKA) and non‐vitamin K antagonists (NOACs). Antiplatelet therapy was used in 38% of the entire cohort at follow‐up, and more commonly among high‐risk patients (41%). Among those on a NOAC at baseline, 22.4% switched to antiplatelet therapy alone after one year. Independent predictors of stroke/transient ischemic attack/peripheral embolism and/or mortality were age, heart failure, chronic kidney disease, prior ischemic stroke, dementia, and chronic obstructive pulmonary disease. CONCLUSIONS: The ChiOTEAF registry provides contemporary data on AF management, including stroke prevention. The poor adherence of NOACs and common use of antiplatelet in these high‐risk elderly population calls for multiple comorbidities management.
format Online
Article
Text
id pubmed-8485828
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84858282021-10-06 One‐year Follow‐up Results of the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry Guo, Yutao Wang, Hao Kotalczyk, Agnieszka Wang, Yutang Lip, Gregory Y.H. J Arrhythm Original Articles BACKGROUND: The high prevalence of atrial fibrillation (AF) in the very elderly population (aged >80 years) might be underestimated. The elderly are at increased risk of both fatal stroke and bleeding. The Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry provides contemporary management strategies among the elderly Chinese patients in the new era of non‐vitamin K antagonists. OBJECTIVE: To present the 1‐year follow‐up data from the ChiOTEAF registry, focusing on the use of antithrombotic therapy, rate vs. rhythm control strategies, and determinants of mortality and stroke. METHODS: The ChiOTEAF registry analyzed consecutive AF patients presenting in 44 centers from 20 Chinese provinces from October 2014 to December 2018. Endpoints of interest were mortality, thromboembolism, major bleedings, cardiovascular comorbidities, and hospital re‐admissions. RESULTS: Of the 7077 patients enrolled at baseline, 657 patients (9.3%) were lost to the follow‐up and 435 deaths (6.8%) occurred. The overall use of anticoagulants remains low, approximately 38% of the entire cohort at follow‐up, with similar proportions of vitamin K antagonists (VKA) and non‐vitamin K antagonists (NOACs). Antiplatelet therapy was used in 38% of the entire cohort at follow‐up, and more commonly among high‐risk patients (41%). Among those on a NOAC at baseline, 22.4% switched to antiplatelet therapy alone after one year. Independent predictors of stroke/transient ischemic attack/peripheral embolism and/or mortality were age, heart failure, chronic kidney disease, prior ischemic stroke, dementia, and chronic obstructive pulmonary disease. CONCLUSIONS: The ChiOTEAF registry provides contemporary data on AF management, including stroke prevention. The poor adherence of NOACs and common use of antiplatelet in these high‐risk elderly population calls for multiple comorbidities management. John Wiley and Sons Inc. 2021-08-11 /pmc/articles/PMC8485828/ /pubmed/34621421 http://dx.doi.org/10.1002/joa3.12608 Text en © 2021 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of Japanese Heart Rhythm Society. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Guo, Yutao
Wang, Hao
Kotalczyk, Agnieszka
Wang, Yutang
Lip, Gregory Y.H.
One‐year Follow‐up Results of the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry
title One‐year Follow‐up Results of the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry
title_full One‐year Follow‐up Results of the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry
title_fullStr One‐year Follow‐up Results of the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry
title_full_unstemmed One‐year Follow‐up Results of the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry
title_short One‐year Follow‐up Results of the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry
title_sort one‐year follow‐up results of the optimal thromboprophylaxis in elderly chinese patients with atrial fibrillation (chioteaf) registry
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485828/
https://www.ncbi.nlm.nih.gov/pubmed/34621421
http://dx.doi.org/10.1002/joa3.12608
work_keys_str_mv AT guoyutao oneyearfollowupresultsoftheoptimalthromboprophylaxisinelderlychinesepatientswithatrialfibrillationchioteafregistry
AT wanghao oneyearfollowupresultsoftheoptimalthromboprophylaxisinelderlychinesepatientswithatrialfibrillationchioteafregistry
AT kotalczykagnieszka oneyearfollowupresultsoftheoptimalthromboprophylaxisinelderlychinesepatientswithatrialfibrillationchioteafregistry
AT wangyutang oneyearfollowupresultsoftheoptimalthromboprophylaxisinelderlychinesepatientswithatrialfibrillationchioteafregistry
AT lipgregoryyh oneyearfollowupresultsoftheoptimalthromboprophylaxisinelderlychinesepatientswithatrialfibrillationchioteafregistry
AT oneyearfollowupresultsoftheoptimalthromboprophylaxisinelderlychinesepatientswithatrialfibrillationchioteafregistry